KRAS and familial pancreatic carcinoma: Remarkably, several researchers have found that approximately 95% of pancreatic cancer patients harbor somatic mutations of theKRAS gene, which is considered the Everest of cancer research [5,6] .KRAS mutations are known to activate the RAF-MEK-ERK pathway, which is regarded as a significant driving force in malignant transformation and tumor development and is closely associated with prognosis [7,8] .